73 results about "Tube formation" patented technology

A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and / or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and / or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.

A PGD(2) receptor (DP) deficiency enhances tumor progression accompanied by abnormal vascular expansion. In tumors, angiogenic endothelial cells highly express DP receptor, and its deficiency accelerates vascular leakage and angiogenesis. Administration of a synthetic DP agonist, BW245C, markedly suppresses tumor growth as well as tumor hyperpermeability in WT mice, but not in DP-deficient mice. In a corneal angiogenesis assay and a modified Miles assay, host DP deficiency potentiates angiogenesis and vascular hyperpermeability under COX-2-active situation, whereas exogenous administration of BW245C strongly inhibits both angiogenic properties in WT mice. In an in vitro assay, BW245C does not affect endothelial migration and tube formation, processes that are necessary for angiogenesis; however, it strongly improves endothelial barrier function via an increase in intracellular cAMP production. PGD(2) / DP receptor is a newly identified regulator of tumor vascular permeability, indicating DP agonism can be exploited as a therapy for the treatment of cancer.

In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and / or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and / or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

A nebulizer kit includes a case body, a flow channel formation member that covers an opening of the case body, an outside air introduction tube erected vertically from a base surface of the flow channel formation member and including a long groove formed in an inner circumferential surface thereof, a compressed air introduction tube below the outside air introduction tube within the case body and extending toward the interior of the outside air introduction tube, and an atomizing area formation member. The atomizing area formation member includes a liquid suction tube formation portion, a baffle, and a baffle support portion that connects the liquid suction tube formation portion and the baffle and that extends toward a side area of the baffle from an outer surface of the liquid suction tube formation portion. The baffle support portion is contained within the long groove of the outside air introduction tube.

The invention discloses a vascular endothelial cell and a preparation method and application thereof; the method for separating the vascular endothelial cell disclosed by the invention comprises the following steps: II type collagenase is used for digesting umbilical vein of umbilical cord in vitro, cells are collected, then culture is carried out and adherent cells are obtained, namely the vascular endothelial cell. The separation method of the invention has simple operation and convenience and practicability; the obtained vascular endothelial cell has high purity, large amount, strong exogenic propagation and a plurality of times of passage, and not only has the functions of phagotrophy and tube formation, but also has the function of inhibiting progenitor cells to develop into dendritic cells; therefore, the invention establishes a stable technical system for the separation and culture of the vascular endothelial cell and lays the foundation for the study and the application of the endothelial cell.

The invention provides a small molecular non-coding RNA (named hsa-miR-29b) and use thereof. In the invention, in-vitro tube formation experiments and nude mouse tumorigenicity and immunohistochemistry experiments are performed, wherein the results of the in-vitro tube formation experiments indicate that the in-vitro restoration of the expression of the hsa-miR-29b can obviously inhibit angiogenesis induced by tumor cells; and the results of the nude mouse tumorigenicity and immunohistochemistry experiments indicate that the in-vivo restoration of the expression of the hsa-miR-29b can obviously inhibit the in-vivo tumorigenic capacity and angiogenic capacity of tumor cells and therefore can inhibit tumor hematogenous metastasis. Therefore, the hsa-miR-29b can be used for preparing medicines for inhibiting tumor cell induced angiogenesis, anti-tumor angiogenesis medicines, antitumor medicines and anti-tumor hematogenous metastasis medicines.

The invention discloses a mimic short peptide 7B of endothelial cell growth factor VEGF antigen epitope and an application thereof. The amino acid sequence of the mimic short peptide 7B is FKPSCVPLMRCGGCCN and the nucleotide sequence is TTCAAACCGTCCTGCGTTCCGCTGATGCGTTGCGGTGGTTGTGCAACG. In vitro experiments show that the mimic short peptide 7B of the invention has obvious inhibiting effect during the processes of endothelial cell proliferation and tube formation and the tumor cell proliferation and migration. Therefore, the mimic short peptide 7B of the invention can be used for preparing peptide vaccines, tumor angiogenesis inhibitor or tumor-oriented drugs, and has great reference value on diagnosing and predicting tumorigenesis by utilizing VEGF receptor as a target, discussing development of small molecular peptides on the tumor angiogenesis inhibitors, and developing and researching tumor-oriented drugs.

The invention discloses an endothelial progenitor cell (EPC) culture method. The culture method comprises the following steps: inoculating human peripheral blood mononuclear cells in a cell culture bottle coated by I-type rat tail collagen, adding a DMEM culture medium in the cell culture bottle, putting the cell culture bottle in an incubator with the temperature of 37 DEG C, the CO2 content of 5 percent and the humidity of 95 percent for culturing; carrying out EPC digestion passage; then carrying out flow cytometric analysis on EPC; carrying out EPC immunofluorescence assay; carrying out a cell proliferative assay; carrying out a single cell clonogenic assay; carrying out FITC-UEA-1 extracellular adsorption and endocytosis Dil-acLDL experimental measurement; and carrying out an in-vitro tube formation experiment. The EPC culture method is simple, convenient and feasible. With the adoption of the EPC culture method, the cost can also be greatly lowered; the high-purity I-type rat tail collagen is prepared by the EPC culture method and used for culturing EPC by coating the cell culture bottle, and the culture medium which is low in cost is also adopted, so that the EPC is successfully cultured from human peripheral blood; through identification, the EPC cultured by the method disclosed by the invention has the phenotypic characteristics and the functions of the EPC cultured by the conventional method.

The invention relates to an engine plastic intake manifold, which is divided into upper and lower pieces, which are formed by vibration friction welding, one of which has friction ribs at the welding position, and the other has welding ribs at the welding position, and overflows on both sides of the welding ribs Material trough; characterized in that: the cross-section of the welding rib is trapezoidal structure. Due to the use of trapezoidal cross-section welding ribs in this structure, the volume of the overflow tank on the side of the inner air passage is larger than that of the traditional structure, and can accommodate more hot melt, which can avoid the leakage of the air passage in the intake manifold. Form flash to ensure the surface finish of the air passage in the intake manifold.

AC133+ / CD34+ cells isolated from human bone marrow can be stimulated with the pro-angiogenic factors VEGF, bFGF, and heparin, resulting in the generation of a population of cells that is adherent and possesses many of the same properties as mature endothelial cell types, HMVECs and HUVECs. The newly-formed, endothelial-like cells are referred as adherent endothelial precursor cells (aEPCs); these cells appear to be intermediates between haematopoietic stem cells (HSCs) and mature endothelial cells. Direct comparison of aEPCs with HMVECs and HUVECs in several in vitro functional assays, such as tube formation, migration, invasion, and expression of cells surface markers, reveals differences and similarities. In a Matrigel™ matrix angiogenesis assay the aEPCs form vessels in vivo and interact with human ovarian cancer cells. Mouse cell lines that are useful models for tumor endothelial cells are identified by determining mRNA and protein expression levels of murine homologs of tumor endothelial markers. Mouse cell lines selected as models for tumor endothelial cells can be used to evaluate pro-angiogenic and anti-angiogenic factors.

The invention discloses a three-dimensional cell co-culture model based on PDMS (polydimethylsiloxane). The three-dimensional cell co-culture model comprises a model body, wherein a left culture pool and a right culture pool are arranged on the inner side of the model body, an interlayer is arranged between the left culture pool and the right culture pool, an opening communicating the left culture pool with the right culture pool is formed in the interlayer, and stoppers jointed with the side face of the interlayer are arranged in the left culture pool and the right culture pool. According to the three-dimensional cell co-culture model based on PDMS, a co-culture system of two kinds of cells is established in the same plane so as to dynamically observe the interaction of the two kinds of cells, cell migration, chemotaxis, invasion and tube formation tests can be carried out, molecular biology detection can be conveniently carried out on the cells in situ or the cells are connected to perform the detection, and in addition, the defect that a vertical co-culture method cannot eliminate gravity interference is overcome; and the three-dimensional cell co-culture model can be repeatedly used and has the advantages of being simple and practicable, good in repeatability, cheap, safe and the like. The invention further discloses a preparation method of the model. The preparation method is simple in technique, liable to operate and easy to control.

A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and / or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and / or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.

The present application discloses angiogenic peptides that cause intracellular calcium release in target cells and thereby induce proliferation, migration, and capillary-like tube formation in primary cultured endothelial cells. The angiogenic peptides can be used for preventing and / or treating angiognesis-related conditions, especially wound healing, treating foot and leg ulcers in a subject, etc. In addition, the angiogenic peptides can be used for cosmetics a constituent of cosmetics for aged skin, for examples, anti-wrinkle and skin whitening.

The present application discloses roles for miR-93 in treating hypoxia and ischemia. Endothelial cells (HUVEC) and myocytes (C2C12) expressed miR-93 and up-regulated miR-93 in response to hypoxia and serum starvation. Over-expression of miR-93 in HUVECs promoted cell proliferation, prevented hypoxia-induced apoptosis, and enhanced endothelial cell tube formation. miR-93 knockdown in HUVECs resulted in increased hypoxia-induced apoptosis and decreased tube formation. Over-expression or knockdown of miR-93 in myocytes resulted in reduced or increased hypoxia-induced apoptosis, respectively. Down-regulation of miR-93 in C57BL / 6 mice with antagomiR resulted in attenuated perfusion recovery (% non-ischemic leg at day-21: Scramble 85.22.9 vs. AntagomiR-93 67.96). Over-expression of miR-93 in BALB / C mice improved perfusion recovery (% non-ischemic leg at day 21: PremiR-93 757.5 vs. Scramble 59.62.5). The present invention encompasses the use of miR-93 and regulation of miR-93 to treat and prevent hypoxia, ischemia, and other injuries, diseases, disorders, and conditions associated with ischemia.

A nebulizer kit includes a case body, a flow channel formation member that covers an opening of the case body, an outside air introduction tube erected vertically from a base surface of the flow channel formation member and including a long groove formed in an inner circumferential surface thereof, a compressed air introduction tube below the outside air introduction tube within the case body and extending toward the interior of the outside air introduction tube, and an atomizing area formation member. The atomizing area formation member includes a liquid suction tube formation portion, a baffle, and a baffle support portion that connects the liquid suction tube formation portion and the baffle and that extends toward a side area of the baffle from an outer surface of the liquid suction tube formation portion. The baffle support portion is contained within the long groove of the outside air introduction tube.

The invention relates to a composition for angiogenesis inhibition comprising a peroxidasin inhibitor as an effective ingredient, and more particularly, to a method of screening angiogenesis inhibitor, which includes steps of treating a test agent, and analyzing peroxidasin gene expression or protein activity, and comparing peroxidasin gene expression or protein activity between a case treated with the test agent and a case not treated with the test agent. Accordingly, since the inhibitor of the peroxidasin expression or protein activity according to the present invention can effectively inhibit migration, proliferation and tube formation of endothelial cells, the inhibitor can be effectively used for preventing or treating a variety of diseases or conditions of the diseases derived from abnormal regulation of angiogenesis.

The invention relates to new application of alantolactone, in particular to application of the alantolactone serving as an anti-angiogenesis drug. The application has the advantages that the activity of an HUVEC (Human Umbilical Vein Endothelial Cell) is detected through a CCK-8 method, and a cell mobility inhibition experiment, a cell migration inhibition experiment, a tube formation inhibition experiment, an in-vivo anti-angiogenesis activity experiment and the like show that the alantolactone can effectively resist angiogenesis. The application shows that the alantolactone has an inhibition effect on an MDA-MB-231 breast tumor and has a prospect of treating a breast cancer. A first research on a VEGFR2 and downstream signal passageway shows that the alantolactone can obviously inhibit phosphorylation of the VEGFR2 and also obviously inhibit phosphorylation of VEGFR2 downstream signal molecules including PLC(gamma)1, FAK, Src and AKT.

The invention relates to a process method for producing an inclined vertical rib structure rotor support frame center body of a large-scale vertical generator. The process method comprises the steps of center tube formation after center tube and upper and lower annular plate stock preparation, split welding after center tube formation, inner and outer surface processing and narrow gap submerged arc welding divided edge processing. The center tube, a rib plate and the upper and lower annular plates are assembled, a combined body of the center tube and the upper and lower annular plate is hoisted onto a rolling wheel frame. Welding seams between the center tube and the upper and lower annular plates are welded by a welding method of the narrow gap submerged arc welding. The process method belongs to the significant improvement on the manufacture technology of the inclined vertical rib structure rotor support frame center body of the large-scale vertical generator. The workpiece size stability and the manufacture quality are greatly improved. The process method has the advantages that the operation is easy, the welding cost is low, at least a half of the manual cost is saved, the production period is saved by 76 percent, and the production efficiency is improved by about 4.17 times.

The invention discloses a mimic short peptide 12B of endothelial cell growth factor VEGF antigen epitope and an application thereof. The amino acid sequence of the mimic short peptide 12B is KARQLELNERTCRCDK and the nucleotide sequence is AAAGCTCGTCAGCTGGAACTGAACGAACGTACCTGCCGTTGCGACAAA. In vitro experiments show that the mimic short peptide 12B of the invention has obvious inhibiting effect during the processes of endothelial cell proliferation and tube formation and the tumor cell proliferation and migration. Therefore, the mimic short peptide 12B of the invention can be used for preparing peptide vaccines, tumor angiogenesis inhibitor or tumor-oriented drugs, and has significant reference value on diagnosing and predicting tumor tumorigenesis by utilizing VEGF receptor as a target, discussing development of small molecular peptides on the tumor angiogenesis inhibitors, and developing and researching tumor-oriented drugs.

The present invention is based on our work with E-cadherin, including soluble portions of this integral membrane glycoprotein. The compositions of the present invention include therapeutically effective amounts of a first agent that targets epitopes within one or more of the EC2-EC5 subdomains of the ectodomain of E-cadherin (induing these domains in the shed sEcad fragment) and a second agent that inhibits one or more of: endothelial tube formation; angiogenesis; the human epidermal growth factor receptor family (i.e. HER1-4); an insulin-like growth factor 1 receptor (IGF-1R); any other receptor tyrosine kinase receptor family member; the P13K-MAPK pathway; and the P13K / Akt / mTOR pathway. The compositions can be used in the treatment of epithelial cancers, and may effectively inhibit cellular proliferation, migration, and / or invasiveness. Thus, the present compositions can be used to inhibit tumor growth and metastasis. The present compositions can be used in the treatment of "triple negative" breast cancer patients (in whom breast cancer cells test negative for estrogen receptors, progesterone receptors, and HER2), as well as HER2 -positive and other HER2 -negative tumors. In addition to therapeutic and prophylactic treatment methods, the invention features methods in which cancer is staged depending on the relative amounts of full-length (FL) E-cadherin and soluble E-cadherin (sEcad) and / or with another predictive biomarker for cancer. The greater the amount of sEcad relative to the amount of FL E-cadherin, the more advanced the cancer.

The invention relates to the field of medicines, in particular to a new application of Bangia fusco-purpurea polysaccharide, especially to an application of the Bangia fusco-purpurea polysaccharide inpreparation of a medicine for promoting wound healing. The results showed that the Bangia fusco-purpurea polysaccharide had no toxicity to human umbilical vein endothelial cells (HUVEC) and human skin fibroblasts (HSF), and could promote the migration and tube formation of the human umbilical vein endothelial cells (HUVEC) and obviously promote the healing of human umbilical vein endothelial cells (HUVEC) wounds.

The present invention relates to a use of mutant haptoglobin having angiogenesis-promoting activity and, more particularly, to a mutant haptoglobin polypeptide, a recombinant vector containing a polynucleotide encoding the polypeptide, or a composition for promoting angiogenesis containing, as an active ingredient, a transformant transformed with the recombinant vector. The mutant haptoglobin according to the present invention includes an amino acid sequence of SEQ ID NO: 1 in which the 143rd amino acid is substituted with an amino acid other than Arg. The mutant haptoglobin according to the present invention has excellent angiogenesis-promoting activity and excellent capillary-like tube formation capability as compared with wild-type haptoglobin, and promotes cell migration, and thus is useful as a therapeutic agent for treating diseases caused by non-angiogenesis.

The invention belongs to the technical field of medicine, and relates to application of a rheumatic pain-relieving traditional Chinese medicinal composition to preparation of an anti-angiogenesis medicament. As proved by human umbilical vein endothelial cell (HUVEC) tube formation assay, MTT, Transwell migration and invasion as well as adhesion experiments, rat aorta ring angiogenesis experiments,and tumor angiogenesis experiments, the rheumatic pain-relieving traditional Chinese medicinal composition can remarkably inhibitthe proliferation, migration, invasion, adhesion and tube forming capability of endothelial cells, and remarkably inhibit the generation of rat aorta ring blood vessels and implanted tumor blood vessels, indicating that the rheumatic pain-relieving traditional Chinese medicinal composition can be applied to the preparation of ananti-angiogenesis medicament.

The invention discloses a device for controlling spiral lamp forming process, which comprises a conical internal mold provided on the surface thereof with a spiral groove; a flexible lamp wound inside the groove of the internal mold to form a spiral lamp; and a left half-mold and a right half-mold that are respectively provided therein with an internal holding chamber and jointed on the surface of the spiral lamp to fix the shape of the spiral lamp. The diameters of the upper end and the lower end of the formed lamp are different, thus resulting in conical shape in longitudinal direction, so as to increase luminescence and transmission space and improve luminescence efficiency of the spiral lamp.

A thermal transfer means comprising, fluidly in series: a fluid supply conduit having a fluid inlet (41) adapted for connection to receive fluid from an outlet of a heat source; a heat exchanger (40) comprising a heat exchanger tube having at least one heat exchanger element disposed thereon; and a fluid delivery conduit (42) having a fluid outlet adapted for connection to deliver fluid to an inlet of a heat source. The fluid supply conduit, heat exchanger tube and fluid delivery conduit are integrally formed from a common tube formation fabricated from a single material. The thermal transfer means is suitable for inclusion into a thermal transfer system, for example on a vehicle, for example to serve as an integral cooling line and / or space heater.

The invention relates to a holding device used for formation of a spiral energy-saving lamp tube, which comprises a cylinder provided with a piston rod and a cylinder body and a motion bar, wherein the middle portion of the piston rod is opened with a through-hole along the axis direction, the motion bar is glidingly arranged in the through-hole, the motion bar is opened with a air cavity along the axis direction, and the front end portion of the motion bar is tubular shape, the rear end portion of the motion bar is provided with an air inlet which is capable of being open and closed and connects the air cavity and the outer portion, the front end portion is sealed and connected with a dismountable spiral energy-saving lamp tube, the air cavity is only capable of being communicated with the outer portion via the open position and the air inlet, a spacing device is arranged between the front end portion of the piston rod and the motion bar, the spacing device is capable of leading the motion bar stop sliding when sliding frontward in a certain position relative to the piston bar. The invention has the advantages of simple structure, low production cost, and can be prepared only by transforming the normal thin cylinder. Using the invention is capable of achieving three key steps as clamping of spiral energy-saving lamp tubes in the process of automatic formation, inflation and detachment from clamping.

The invention provides a self-curling membrane agent applied to nerve repair and a preparation method thereof. The self-curling membrane agent is a membrane agent which is composed of three layers ofA, B and C and has the thickness of 60-120 [mu]m. The main components of the A layer are indocyanine green and silk fibroin, the main components of the B layer comprise cyclic dipeptide and calcium alginate, and the main components of the C layer comprise cyclic dipeptide and sodium alginate. The membrane agent directionally curls in water to form a continuous hollow tube, the A layer is arrangedinside, the C layer is arranged outside, and the membrane agent quickly becomes a closed lumen structure under the irradiation of near red light. The invention provides a new method for nerve dockingand casing repair in nerve defects, realizes the requirements of simple and convenient manufacture, convenient tube formation, controllable size and convenient application, and has wide application prospect.

The invention relates to an underground hot-melting cast tube wall protection technology. Hard and compact tube wall is formed by the following steps: fusing a tube formation material underground, shaping the fused tube formation material, and cooling to solid into tube wall. The technology is simple and has wide application range, the use cost is low, thus being capable of realizing the purposes of reducing maintenance cost of a rockshaft, prolonging the service life of the rockshaft, and effectively saving energy and reducing emission.

The invention is related to the field of civil engineering, particularly related to the translucent roofs of buildings, and regards the production of polycarbonate dome structure or translucent material, made of double lens and tube formation, which allows the installation and mounting of the same in-line, in the roofing structures, targeting design and extending day light in the inner area of buildings, even at low climatic condition, reducing the passage of excessive heat into the environment to be illuminated. In addition to reducing heat passage by approximately 30%, its use installation will take place linearly and non-point, so that natural light is distributed more homogeneously in the environment. The material for its manufacture can come from prismatic polycarbonate, acrylic or other compatible material and its manufacturing process adopts vacuum system forming (thermoforming).